Zobrazeno 1 - 10
of 26
pro vyhledávání: '"Céline Montavon"'
Autor:
Nicole E. Speck, Julia Stoffel, Séverin Wendelspiess, Christian Appenzeller-Herzog, Kristin M. Schaefer, Loraine P. Kouba, Florian Rüter, Céline Montavon, Viola Heinzelmann-Schwarz, Martin D. Haug, Dirk J. Schaefer, Tarek Ismail, Elisabeth A. Kappos
Publikováno v:
Current Oncology, Vol 31, Iss 10, Pp 6300-6313 (2024)
Background: Patient-reported outcome measures (PROMs) have gained increased importance in assessing outcomes after reconstructive surgery. This also applies to the reconstruction of vulvoperineal defects after resection of gynecological or colorectal
Externí odkaz:
https://doaj.org/article/1478f41b990a45709ca0281ec4a9f688
Autor:
Tibor A. Zwimpfer, Kathrin Scherer, Andreas Schötzau, Viola Heinzelmann‐Schwarz, Karin Hartmann, Marcus Vetter, Céline Montavon
Publikováno v:
Cancer Medicine, Vol 13, Iss 1, Pp n/a-n/a (2024)
Abstract Background Exposure to paclitaxel and carboplatin has the risk of developing hypersensitivity reactions (HSRs), which could necessitate using less effective treatments to avoid anaphylaxis. Desensitization to platinum and taxane HSRs can be
Externí odkaz:
https://doaj.org/article/8934956619654e18aaa23831836027d0
Autor:
Evelyne Bischof, Fabienne D. Schwab, Elena Laura Georgescu Margarint, Céline Montavon, Iris Zünti, Anna Schollbach, Andreas Schötzau, Anna Hirschmann, Julia Landin, Christian Meier, Kurzeder Christian, Marcus Vetter
Publikováno v:
Bone Reports, Vol 16, Iss , Pp 101160- (2022)
Aim: In patients with postmenopausal hormone receptor-positive breast cancer (ER + eBC), aromatase inhibitors (AIs) are widely used for effective relapse prevention. However, AIs reduce bone density and increase bone-related events (BREs). Alongside
Externí odkaz:
https://doaj.org/article/9fcf3650c6bc4fe39813713592663c01
Autor:
Florence Baettig, Tatjana Vlajnic, Marcus Vetter, Katharina Glatz, Jürgen Hench, Stephan Frank, Michel Bihl, Roberto Lopez, Michael Dobbie, Viola Heinzelmann-Schwarz, Céline Montavon
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 7, Iss 1, Pp 1-7 (2019)
Abstract Background Treatment options for advanced cervical cancer are limited and patients experiencing recurrence after first-line cisplatin-based chemotherapy and bevacizumab have a poor prognosis. A recent phase II study in advanced cervical canc
Externí odkaz:
https://doaj.org/article/e39dc502a1674315931973a14cfa66c6
Autor:
Céline Montavon Sartorius, Andreas Schoetzau, Henriette Kettelhack, Daniel Fink, Neville F Hacker, André Fedier, Francis Jacob, Viola Heinzelmann-Schwarz
Publikováno v:
PLoS ONE, Vol 13, Iss 3, p e0195213 (2018)
The relationship between ABO blood groups (BG) and risk of incidence in cancers including gynecological cancers has been widely studied, showing increased incidence risk for BG A patients. As available data are inconsistent we investigated whether BG
Externí odkaz:
https://doaj.org/article/232f9b0bf3844763856f701e77ff312b
Autor:
Alexandra Maria Knipprath-Mészáros, Alessandra Tozzi, Annkathrin Butenschön, Hubertina Reina, Andreas Schoetzau, Céline Montavon, Viola Heinzelmann-Schwarz, Gwendolin Manegold-Brauer
Publikováno v:
Gynecologic Oncology. 174:182-189
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::61e0b0447f11bc7e45e6a47e6c4fd4dc
https://doi.org/10.1016/j.ygyno.2023.05.005
https://doi.org/10.1016/j.ygyno.2023.05.005
Autor:
Marcus Vetter, Sylvia Stadlmann, Evelyne Bischof, Elena Laura Georgescu Margarint, Andreas Schötzau, Gad Singer, Viola Heinzelmann-Schwarz, Céline Montavon
Publikováno v:
International Journal of Molecular Sciences; Volume 23; Issue 22; Pages: 14242
Endocrine therapy is an effective treatment for low-grade serous ovarian cancer. However, the role of estrogen and progesterone receptors as biomarkers for high-grade serous ovarian cancer (HGSOC) is yet to be elucidated because not all estrogen and
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::70e0b14fbc72dda32ea94904e4579548
Publikováno v:
The EBCOG Postgraduate Textbook of Obstetrics & Gynaecology
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::3388f83f880527f27d0f36d908823bd6
https://doi.org/10.1017/9781108582322.043
https://doi.org/10.1017/9781108582322.043
Publikováno v:
The EBCOG Postgraduate Textbook of Obstetrics & Gynaecology
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::3d6d3066ff2bdf46de59d69638ef2233
https://doi.org/10.1017/9781108582322.042
https://doi.org/10.1017/9781108582322.042
Autor:
Evelyne Bischof, Fabienne D. Schwab, Elena Laura Georgescu Margarint, Céline Montavon, Iris Zünti, Anna Schollbach, Andreas Schötzau, Anna Hirschmann, Julia Landin, Christian Meier, Kurzeder Christian, Marcus Vetter
Publikováno v:
Bone Reports
Bone Reports, Vol 16, Iss, Pp 101160-(2022)
Bone Reports, Vol 16, Iss, Pp 101160-(2022)
Aim: In patients with postmenopausal hormone receptor-positive breast cancer (ER + eBC), aromatase inhibitors (AIs) are widely used for effective relapse prevention. However, AIs reduce bone density and increase bone-related events (BREs). Alongside
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::612ea32fb3e132f733b27e741718ea67
http://europepmc.org/articles/PMC8685978
http://europepmc.org/articles/PMC8685978